Evommune, Inc. EVMN
$5.99
-11.00%
at last close
Market Cap$244.25 million
P/E Ratio—
Div Yield—
Volume223.0K
52-Week Range
$4.94$33.20
Analyst Ratings
- Consensus
- Buy — 9 Buy · 3 Hold · 0 Sell (12 analysts)
- Avg. Price Target
- $31.11 (+419.4% upside)
Key Stats
- Today's Range
- $5.94 – $6.82
- 50-Day Range
- $4.94 – $14.44
- 52-Week Range
- $4.94 – $33.20
- Volume
- 223K shs
- Average Volume
- 978K shs
- Market Cap
- $244.25 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.28%
- Days to Cover
- 1.00
About Evommune, Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
Related Stocks
Compare head-to-head: EVMN vs LLY·EVMN vs JNJ·EVMN vs ABBV·EVMN vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.